KZA kazia therapeutics limited
Add to My Watchlist 0.00% ! 8.0¢

Chasing a Cure for GBM

  1. Rich&Poor
    1,206 Posts.
    lightbulb Created with Sketch. 941
    clock Created with Sketch.
    12/06/20
    16:49
    Post #: 45192770
    Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial.
    15 May 2020
    Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

    Paxalisib will have its own trial design for the adaptive GBM AGILE trial.

    https://www.onclive.com/view/chasing-a-cure-for-gbm-investigators-test-multiple-regimens-in-novel-trial

    Regards.

    KZA Price at posting: 41.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 9  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS First assay results returned from ongoing drilling at Gold Duke Project
right-arrow Created with Sketch.
NEWS The biggest ASX director trades from the last week
right-arrow Created with Sketch.
NEWS ANSTO continuous piloting confirms exceptional rare earth recoveries
right-arrow Created with Sketch.
AII A critical metal, a broken supply chain, surging demand, and a Western producer ready to deliver
right-arrow Created with Sketch.
NEWS Explore the latest ASX Market News
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 025 – Locksley rap video gives Hilltop Hoods run for money
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.